Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 7/20 | 0.51 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | PLAT | P00750 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6979011 | 0.82 | S1PR1 (0.46) | S1PR1S1PR3ALDH1A1PLATCYP11B1 | |
| SCHEMBL12601790 | 0.80 | S1PR1 (0.46) | S1PR1S1PR3L3MBTL1KDM4ETDP1 | |
| SCHEMBL15495466 | 0.80 | PDK2 (0.53) | S1PR1ALDH1A1PDK2L3MBTL1TP53 | |
| SCHEMBL16481962 | 0.79 | L3MBTL1 (0.44) | S1PR1S1PR3ALDH1A1CYP11B1CYP11B2 | |
| SCHEMBL6785923 | 0.78 | S1PR1 (0.61) | S1PR1S1PR3ALDH1A1L3MBTL1TP53 | |
| SCHEMBL6782004 | 0.77 | S1PR1 (0.56) | S1PR1S1PR3ALDH1A1PLATTP53 | |
| SCHEMBL6780851 | 0.76 | S1PR1 (0.55) | S1PR1S1PR3ALDH1A1PLATL3MBTL1 | |
| SCHEMBL6779997 | 0.76 | NPC1 (0.60) | S1PR1S1PR3ALDH1A1PLATL3MBTL1 | |
| SCHEMBL6780809 | 0.76 | S1PR1 (0.67) | S1PR1S1PR3PLAT | |
| SCHEMBL15236975 | 0.76 | S1PR1 (0.48) | S1PR1S1PR3ALDH1A1PDK2PLAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183276-B2 | Therapeutic agents | MERCK SHARP & DOHME CORP. | 2012-05-22 | — | — | US | disclosed |
| US-20100324029-A1 | THERAPEUTIC AGENTS | MERCK SHARP & DOHME CORP. | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324029-A1 | THERAPEUTIC AGENTS | PSEN2, PSEN1, BACE2 | S1PR1 2711/4885S1PR3 2765/4885ALDH1A1 1185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.